<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496169</url>
  </required_header>
  <id_info>
    <org_study_id>eucaLimus2015</org_study_id>
    <nct_id>NCT02496169</nct_id>
  </id_info>
  <brief_title>Prospective multicEntric NonranDomized Registry</brief_title>
  <acronym>ExPEND</acronym>
  <official_title>A Prospective, Multi-centric, Nonrandomised Interventional Study of a Sirolimus-eluting Stent With a Biodegradable Polymer for Percutaneous Coronary Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eucatech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CERES GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eucatech AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the eucaLimus Sirolimus&#xD;
      Eluting stent system in patients with de novo coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lumen Revascularisation (TLR)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Clinical driven TLR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lumen Revascularisation (TLR)</measure>
    <time_frame>1 month, 6 months, 24 months post procedure</time_frame>
    <description>Clinical driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death</measure>
    <time_frame>1 month, 6 months, 12 months, 24 months post procedure</time_frame>
    <description>MI attributed to the target vessel and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality</measure>
    <time_frame>24 months post procedure</time_frame>
    <description>any MI and any revascularization, target vessel revascularization or revascularization of nontarget vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 month, 6 months, 12 months, 24 months post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>eucaLimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Coronary Intervention (PCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eucaLimus</intervention_name>
    <description>Percutaneous Coronary Intervention (PCI)</description>
    <arm_group_label>eucaLimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years or the minimum age required for legal adult consent in the&#xD;
             country of enrollment.&#xD;
&#xD;
          2. Subject is an acceptable candidate for Percutaneous Coronary Intervention (PCI).&#xD;
&#xD;
          3. Subject is an acceptable candidate for Emergent Coronary Artery Bypass Grafting&#xD;
             (CABG).&#xD;
&#xD;
          4. Subject has clinical evidence of ischemic heart disease, stable or unstable angina&#xD;
             pectoris or documented silent ischemia.&#xD;
&#xD;
          5. Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either&#xD;
             clopidogrel, prasugrel, ticagrelor or ticlopidine.&#xD;
&#xD;
          6. Subject has provided written informed consent.&#xD;
&#xD;
          7. Subject is willing to comply with study follow-up requirements.&#xD;
&#xD;
        Each target lesion/vessel must meet all of the following angiographic criteria for the&#xD;
        subject to be eligible for the trial:&#xD;
&#xD;
          1. Subject has up to 3 target lesions in up to 3 separate target vessels Subject has up&#xD;
             to 3 target lesions in in up 2 separate target vessels (2 target lesions in 1 vessel&#xD;
             and 1 target lesion in a separate vessel). Subject has 1 target lesions in 1 vessel.&#xD;
&#xD;
          2. Target lesion must be de novo.&#xD;
&#xD;
          3. Target lesion must be in major coronary artery or branch (target vessel).&#xD;
&#xD;
          4. Target lesion must have angiographic evidence of ≥ 50% and &lt; 100% stenosis (by&#xD;
             operator visual estimate)&#xD;
&#xD;
          5. Target lesion must be ≤ 35 mm in length by operator visual estimate.&#xD;
&#xD;
          6. Target vessel Reference Vessel Diameter (RVD) of 2.25mm - 4.00mm by operator visual&#xD;
             estimate.&#xD;
&#xD;
          7. Target lesion must be treatable with a maximum of 1 stents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with&#xD;
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index&#xD;
             procedure. Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study&#xD;
             enrollment.&#xD;
&#xD;
          2. Subject is presenting cardiogenic shock.&#xD;
&#xD;
          3. Subject is pregnant and/or breastfeeding or intends to become pregnant during the&#xD;
             duration of the study.&#xD;
&#xD;
          4. Subject has a known allergy to contrast medium that cannot be adequately&#xD;
             pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and&#xD;
             bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt,&#xD;
             chromium, tungsten and nickel), Polylactic-Co-Glycolic Acid (PLGA), sirolimus&#xD;
&#xD;
          5. Revascularization of any target vessel within 9 months prior to the index procedure or&#xD;
             previous PCI of any non-target vessel within 30 days prior to the index procedure.&#xD;
&#xD;
          6. Planned treatment of a lesion not meeting angiographic inclusion and exclusion&#xD;
             criteria during the index procedure or after the index procedure.&#xD;
&#xD;
          7. Planned surgery within 6 months of index procedure unless dual antiplatelet therapy&#xD;
             can be maintained throughout the peri-surgical period.&#xD;
&#xD;
          8. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the&#xD;
             index procedure.&#xD;
&#xD;
          9. Subjects with active bleeding disorders, active coagulopathy, or any other reason, who&#xD;
             are ineligible for Dual Antiplatelet Therapy (DAPT).&#xD;
&#xD;
         10. Subject will refuse blood transfusions.&#xD;
&#xD;
         11. Subject has documented left ventricular ejection fraction (LVEF) &lt; 30% within 90 days&#xD;
             prior to the index procedure.&#xD;
&#xD;
         12. Subject is dialysis-dependent.&#xD;
&#xD;
         13. Subject has impaired renal function (i.e., blood creatinine &gt; 2.5 mg/dL or 221 μmol/L&#xD;
             determined within 7 days prior to the index procedure).&#xD;
&#xD;
         14. Subject has leukopenia (i.e. &lt; 3,000 white blood cells/mm3), thrombocytopenia (i.e. &lt;&#xD;
             100,000 platelets/mm3) or thrombocytosis (i.e. &gt; 700,000 platelet/mm3).&#xD;
&#xD;
         15. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids&#xD;
             are permitted), or has known life-limiting immunosuppressive or autoimmune disease&#xD;
             (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus&#xD;
             is permitted).&#xD;
&#xD;
         16. Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban,&#xD;
             rivaroxaban or any other agent).&#xD;
&#xD;
         17. Subject has life expectancy of &lt; 1 year.&#xD;
&#xD;
         18. Subject is participating in another investigational (medical device or drug) clinical&#xD;
             study. Subjects may be concurrently enrolled in a study, as long as the study device,&#xD;
             drug or protocol does not interfere with the investigational treatment or protocol of&#xD;
             this study.&#xD;
&#xD;
         19. In the investigator's opinion, subject will not be able to comply with the follow-up&#xD;
             requirements.&#xD;
&#xD;
        Subjects will be excluded from the trial if any of the target lesions/vessels meets any of&#xD;
        the following angiographic criteria:&#xD;
&#xD;
          1. Target lesion is located within a saphenous vein graft or arterial graft.&#xD;
&#xD;
          2. Target lesion involves a side branch of &gt; 2.0 mm in diameter. Note: Lesions within 3&#xD;
             mm of the origin of the right coronary artery may be treated.&#xD;
&#xD;
          3. Target vessel/lesion is excessively tortuous / angulated or is severely calcified,&#xD;
             that would prevent complete inflation of an angioplasty balloon. This assessment&#xD;
             should be based on visual estimation.&#xD;
&#xD;
          4. Target vessel has angiographic evidence of thrombus.&#xD;
&#xD;
          5. Target vessel was treated with brachytherapy any time prior to the index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Pernes, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital privé d' Antony 1 rue Velpeau 92160 Antony, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Giese, Dr.</last_name>
    <phone>+49 7623 7177</phone>
    <phone_ext>103</phone_ext>
    <email>clinicaltrial@eucatech.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Karl, Dipl.-Ing.</last_name>
    <phone>+49 7623 7177</phone>
    <phone_ext>140</phone_ext>
    <email>clinicaltrial@eucatech.de</email>
  </overall_contact_backup>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCA</keyword>
  <keyword>stenosis</keyword>
  <keyword>sirolimus</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

